Rhythm Pharmaceuticals, Inc.

Biotechnology • Healthcare • Boston, MA, United States • RYTM (NGM)

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. The company was founded in 2008 and is headquartered in Boston, Massachusetts.

857 264 4280 222 Berkeley Street, Boston, MA 02116, United States

Stock Performance (90 Days)

Data through Dec 29, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Rhythm Pharma Hits Record High On Unexpected Obesity-Tied Win - Investor's Business Daily

Investor's Business Daily • Dec 11

Rhythm Pharmaceuticals Stock Rises After Positive Study Data For Setmelanotide In Treating Genetic Disorder - Stocktwits

Stocktwits • Dec 11

Is It Too Late to Invest in Rhythm Pharmaceuticals After Its 2025 Rally? - Yahoo Finance

Yahoo Finance • Dec 12

Guggenheim raises Rhythm Pharmaceuticals stock price target on promising PWS data - Investing.com

Investing.com • Dec 17

Rhythm Pharmaceuticals (Nasdaq: RYTM) sees BMI, hunger drops in PWS Phase 2 trial - Stock Titan

Stock Titan • Dec 11

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has RHYTHM PHARMACEUTICALS, INC. had layoffs?

No layoff events have been recorded for RHYTHM PHARMACEUTICALS, INC. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does RHYTHM PHARMACEUTICALS, INC. have?

RHYTHM PHARMACEUTICALS, INC. has approximately 283 employees.

What industry is RHYTHM PHARMACEUTICALS, INC. in?

RHYTHM PHARMACEUTICALS, INC. operates in the Biotechnology industry, within the Healthcare sector.

Is RHYTHM PHARMACEUTICALS, INC. a publicly traded company?

Yes, RHYTHM PHARMACEUTICALS, INC. is publicly traded under the ticker symbol RYTM on the NGM. The company has a market capitalization of approximately $7.51 billion.

Where is RHYTHM PHARMACEUTICALS, INC. headquartered?

RHYTHM PHARMACEUTICALS, INC. is headquartered in Boston, MA, United States at 222 Berkeley Street, Boston, MA 02116, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.